文献速递骨质疏松与代谢性骨病

罗莫佐单抗与抗骨吸收治疗的序贯重要性

Romosozumab and antiresorptive treatment: the importance of treatment sequence.
PubMed 文献 · Osteoporos Int · 2022-02-15

本分析回顾了罗莫佐单抗在抗骨吸收药物(阿仑膦酸钠或地舒单抗)之前或之后给药的随机临床试验,评估治疗顺序对罗莫佐单抗反应的影响。结果表明,先使用罗莫佐单抗再序贯抗骨吸收治疗,髋部和脊柱骨密度增加幅度及骨密度应答率均大于相反顺序。

要点

  • 先罗莫佐单抗后抗骨吸收治疗较相反顺序使髋部和脊柱骨密度增幅更大。
  • 罗莫佐单抗初始治疗1年,全髋骨密度增加6.2%和6.0%,腰椎骨密度增加13.7%和13.1%。
  • 罗莫佐单抗/地舒单抗序贯后全髋骨密度增益≥6%的患者比例为69%,地舒单抗/罗莫佐单抗序贯为15%。

核心结论

  • 本研究中,先使用罗莫佐单抗再使用抗骨吸收药物,较相反顺序获得更大的平均骨密度增加和更高的骨密度应答率。

研究设计与样本

  • 本分析回顾了罗莫佐单抗在抗骨吸收药物之前(ARCH、FRAME)或之后(STRUCTURE、2期扩展研究)给药的随机临床试验。

主要发现

  • ARCH和FRAME中罗莫佐单抗初始治疗1年,全髋骨密度分别增加6.2%和6.0%,腰椎骨密度分别增加13.7%和13.1%。
  • 阿仑膦酸钠后使用罗莫佐单抗1年(STRUCTURE)全髋骨密度增加2.9%,腰椎增加9.8%;地舒单抗后使用罗莫佐单抗1年(2期扩展)全髋增加0.9%,腰椎增加5.3%。
  • 2年间,罗莫佐单抗/阿仑膦酸钠序贯全髋和腰椎骨密度分别增加7.1%和15.2%,罗莫佐单抗/地舒单抗序贯分别增加8.5%和16.6%,地舒单抗/罗莫佐单抗序贯分别增加3.8%和11.5%。
  • 先使用罗莫佐单抗较相反顺序有更大比例患者达到骨密度增益≥6%,尤其是全髋(罗莫佐单抗/地舒单抗序贯后69%;地舒单抗/罗莫佐单抗序贯后15%)。

关键数值与推荐

  • 全髋和腰椎骨密度百分比变化及应答率(骨密度增益≥3%和≥6%)在第1年和第2年评估(STRUCTURE仅1年数据)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: To evaluate whether treatment sequence affects romosozumab response, this analysis reviewed studies where romosozumab was administered before or following an antiresorptive (alendronate or denosumab). Initial treatment with romosozumab followed by an antiresorptive resulted in larger increases in bone mineral density of both hip and spine compared with the reverse sequence. INTRODUCTION: Teriparatide followed by an antiresorptive increases bone mineral density (BMD) more than using an antiresorptive first. To evaluate whether treatment sequence affects romosozumab response, we reviewed randomized clinical trials where romosozumab was administered before (ARCH, FRAME) or following (STRUCTURE, Phase 2 extension) an antiresorptive (alendronate or denosumab, respectively). METHODS: We evaluated BMD percentage change for total hip (TH) and lumbar spine (LS) and response rates (BMD gains ≥ 3% and ≥ 6%) at years 1 and 2 (except STRUCTURE with only 1-year data available). RESULTS: With 1-year romosozumab initial therapy in ARCH and FRAME, TH BMD increased 6.2% and 6.0%, and LS BMD increased 13.7% and 13.1%, respectively. When romosozumab was administered for 1 year after alendronate (STRUCTURE) or denosumab (Phase 2 extension), TH BMD increased 2.9% and 0.9%, respectively, and LS BMD increased 9.8% and 5.3%, respectively. Over 2 years, TH and LS BMD increased 7.1% and 15.2% with romosozumab/alendronate, 8.5% and 16.6% with romosozumab/denosumab, and 3.8% and 11.5% with denosumab/romosozumab, respectively. A greater proportion of patients achieved BMD gains ≥ 6% when romosozumab was used first, particularly for TH, versus the reverse sequence (69% after romosozumab/denosumab; 15% after denosumab/romosozumab). CONCLUSION: In this study, larger mean BMD increases and greater BMD responder rates were achieved when romosozumab was used before, versus after, an antiresorptive agent. Since BMD on treatment is a strong surrogate for bone strength and fracture risk, this analysis supports the thesis that initial treatment with romosozumab followed by an antiresorptive will result in greater efficacy versus the reverse sequence.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Cosman F, Kendler DL, Langdahl BL, et al. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int. 2022. PMID: 35165774. doi:10.1007/s00198-021-06174-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。